Eikon Therapeutics

EIKN

Market cap $533M

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a robust oncology-focused pipeline. EIKN's ASCO data for EIK1001 in NSCLC showed a 63.1% ORR and favorable safety, but the market response was muted. Cash reserves of $596m provide a runway into 2027 despite high R&D burn; valuation is now below cash, reflecting skepticism.

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma.

MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations on several of its lead programs at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, including updated data for its EIK1001 trial in non-small cell lung cancer (NSCLC) and its highly selective PARP1 inhibitor EIK1003.

Presentations to cover progress across Eikon's most advanced clinical-stage programs Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC”), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities. MILLBRAE, Calif.

MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported first quarter 2026 financial results and provided updates on its lead clinical programs.

Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates.

Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout the week.